SHAREHOLDER ALERT: Weiss Law Investigates Oyster Point Pharma, Inc.

Provided By PR Newswire

Last update: Nov 8, 2022

NEW YORK, Nov. 7, 2022 /PRNewswire/ --

Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Oyster Point Pharma, Inc. ("Oyster Point" or the "Company") (NASDAQ: OYST), in connection with the proposed acquisition of the Company by Viatris Inc. (NASDAQ: VTRS) via tender offer. Under the terms of the merger agreement, the Company's shareholders will receive $11.00 in cash for each share of Oyster Point common stock owned, plus a contingent value right ("CVR") representing the right to receive a potential cash payment of up to $2.00 per share.